Evidence map›Paper›PMID 36307561›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2023

Reward-related predictors of symptom change in behavioral activation therapy for anhedonic adolescents: a multimodal approach.

Christian A Webb, Laura Murray, Anna O Tierney, Erika E Forbes, Diego A Pizzagalli

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02498925 nacompletednot on this map

Examining Reward-Related Predictors and Mechanisms of Change in BA Treatment for Anhedonic Adolescents

TypeinterventionalSponsorMclean HospitalRan2015 to 2023Enrolled80ConditionsAnhedoniaArmsBehavioral Activation
NCT07369115 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Intra-Cellular Therapies, Inc. / "A Randomized, Double-blind, Placebo-controlled, Single Site Study to Evaluate the Efficacy of Lumateperone for the Treatment of Major Depressive Disorder (MDD) and Early Life Trauma in Adult Patients Aged 21 to 70 Years

TypeinterventionalSponsorUniversity of Texas at AustinRan2026 to 2030Enrolled50ConditionsMajor Depressive Diorder, Early Life TraumaArmsLumateperone 42 mg, Placebo
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Self-Schemata and Suicidal Thoughts and Nonsuicidal Self-Injury: Longitudinal and Bidirectional Associations in Adolescent Inpatients.Clinical psychological science : a journal of the Association for Psychological Science · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Christian A WebbHarvard Medical School, Boston, MA, USA. cwebb@mclean.harvard.edu.ORCID 0000-0002-8310-4539
Laura MurrayHarvard Medical School, Boston, MA, USA.
Anna O TierneyMcLean Hospital, Belmont, MA, USA.
Erika E ForbesDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0003-0659-7744
Diego A PizzagalliHarvard Medical School, Boston, MA, USA.ORCID 0000-0002-7772-1143
Harvard University · USMcLean Hospital · USUniversity of Pittsburgh · US

Funding

Neuroimaging Studies of Reward Processing in DepressionR37MH068376 · NIMH · UNIVERSITY OF CALIFORNIA-IRVINE · PI Diego A Pizzagalli · 2016 to 2026
$7.4M
Training In Drug Abuse and Brain ImagingT32DA015036 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI SCOTT E LUKAS · 2002 to 2026
$5.3M
Supplemental: Neural and cognitive propensity for trait rumination in adolescents: a multimodal study with ecological momentary assessments and MRIR01AT011002 · NCCIH · MCLEAN HOSPITAL · PI WEBB, CHRISTIAN ANTHONY · 2021 to 2025
$3.4M
Development of Anhedonia in High-Risk AdolescentsR01MH104418 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FORBES, ERIKA E · 2015 to 2020
$3.1M
Social-Affective Vulnerability to Suicidality among LGBTQ Young Adults: Proximal and Distal FactorsR01MH124900 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FORBES, ERIKA E, SILK, JENNIFER S · 2021 to 2024
$2.9M
Predicting the onset of depression in at-risk adolescents from endophenotype profilesR01MH116969 · NIMH · MCLEAN HOSPITAL · PI WEBB, CHRISTIAN ANTHONY · 2019 to 2024
$2.8M
Examining Reward-Related Predictors and Mechanisms of Change in BA Treatment for Anhedonic AdolescentsK23MH108752 · NIMH · MCLEAN HOSPITAL · PI WEBB, CHRISTIAN ANTHONY · 2015 to 2018
$703k
NCCIH NIH HHS R01 AT011002NIDA NIH HHS T32 DA015036NIMH NIH HHS K23 MH108752NIMH NIH HHS R01 MH104418NIMH NIH HHS R01 MH116969NIMH NIH HHS R01 MH124900NIMH NIH HHS R37 MH068376
6 · The paper itself

Abstract

Anhedonia is a cardinal characteristic of depression which predicts worse treatment outcome and is among the most common residual symptoms following treatment. Behavioral Activation (BA) has been shown to be an effective treatment for depressed adults, and more recently, depressed adolescents. Given its emphasis on systematically and gradually increasing exposure to and engagement with rewarding activities and experiences, BA may be a particularly effective intervention for adolescents experiencing anhedonia and associated reward system dysfunction. In the present study, anhedonic adolescents (AA; n = 39) received 12 weekly sessions of BA and completed a multimodal (i.e., neural, behavioral, and self-report [ecological momentary assessment]) assessment of reward function at pre-treatment and post-treatment (as well as weekly self-report assessments of anhedonia). Typically developing adolescents (TDA; n = 41) completed the same measures at corresponding timepoints. Multilevel models tested pre-treatment reward-related predictors of anhedonia improvement, as well as change in reward measures over the course of BA. Analyses revealed significant reductions in anhedonia following BA treatment. Enhanced pre-treatment neural (striatal) reward responsiveness predicted greater anhedonia improvement. In contrast, baseline self-report and behavioral reward measures did not predict treatment outcome. A group x time interaction revealed greater increases in both reward- and loss-related neural responsiveness among AA relative to TDA adolescents. Consistent with a capitalization (rather than compensatory) model, pre-treatment neural - but not self-report or behavioral - measures of relatively enhanced reward responsiveness predicted better BA outcome. In addition to alleviating anhedonia, successful BA may also increase neural sensitivity to affectively salient (e.g., reward- and loss-related) stimuli among anhedonic youth.

Indexed as

AnhedoniaDepressionAdolescentAdultBehavior TherapyHumansRewardTreatment Outcome

Identifiers

PMID36307561
PMCPMC9938220
OpenAlexW4307774121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.